Revolution of Therapy in Acute Lymphoblastic Leukemia

EP. 1: Molecular Cytogenetic Risk Stratification in ALL

January 22nd 2019

EP. 2: Pediatric-Inspired Regimens in ALL

January 22nd 2019

EP. 3: How Age Affects Treatment Approaches in ALL

January 22nd 2019

EP. 4: Effective Novel Agents in Upfront Treatment of ALL

January 22nd 2019

EP. 5: Considerations of Cytoreduction in ALL

January 22nd 2019

EP. 6: Revolutionizing the Treatment of Ph+ ALL with TKIs

January 22nd 2019

EP. 7: Therapeutic Approaches in Philadelphia-like ALL

January 22nd 2019

EP. 8: Role of MRD Testing in Adult Acute Lymphocytic Leukemia

January 22nd 2019

EP. 9: Time Points in the Assessment of MRD

January 22nd 2019

EP. 10: Monitoring for Relapse in Acute Lymphoblastic Leukemia

January 22nd 2019

EP. 11: Blinatumomab for Patients with MRD-Positive ALL

January 22nd 2019

EP. 12: The Evolving Role of Transplant in ALL

January 22nd 2019

EP. 13: CAR T: Dominant Therapy for B-Cell ALL

January 22nd 2019

EP. 14: Examining the Toxicities of CAR T-cell Therapy

January 22nd 2019

EP. 15: Acute Lymphocytic Leukemia: What's Next

January 22nd 2019

EP. 16: Approaching the Management of Philadelphia-Negative ALL

January 22nd 2019

EP. 17: Treatment Algorithms for Philadelphia-Negative ALL

January 22nd 2019

EP. 18: Ph-Negative ALL: Establishing Blinatumomab's Role in Therapy

January 22nd 2019

EP. 19: Blinatumomab: Safety Data in Ph-Negative ALL

January 22nd 2019

EP. 20: Establishing MRD's Role in ALL Management

January 22nd 2019

NEXT PAGE
PREVIOUS PAGE